Extracellular vesicles can modulate numerous processes starting from proliferation and tissue restore, to chemo-resistance and mobile differentiation. With the introduction of tissue and immunological focusing on, extracellular vesicles are additionally more and more seen as promising vectors to ship peptide-based most cancers antigens to the human immune system.
Despite the medical relevance and therapeutic potential of such ‘cell-free’ approaches, the pure antigen presentation landscape exported in extracellular vesicles remains to be largely uncharted, as a result of the difficult nature of such preparations and analyses. In the context of therapeutic vesicle manufacturing, a essential analysis of the similarity in vesicular antigen presentation can also be urgently wanted. In this work, we in contrast the HLA-I peptide ligandomes of extracellular vesicles towards that of whole-cells of the similar cell line.
We discovered that extracellular vesicles not solely over-represent HLA-B complexes and peptide ligands, but additionally cysteinylated peptides that will modulate immune responses. Collectively, these findings describe the pre-existing provision of vesicular HLA complexes which may be utilized to hold peptide vaccines, in addition to the propensity for various peptide and post-translationally modified ligands to be introduced, and will define essential concerns in devising novel EV vaccination methods.
Bioorthogonal protein labelling allows the examine of antigen processing of citrullinated and carbamylated auto-antigens
Proteolysis is key to many organic processes. In the immune system, it underpins the activation of the adaptive immune response: degradation of antigenic materials into quick peptides and presentation thereof on main histocompatibility complexes, results in activation of T-cells. This initiates the adaptive immune response towards many pathogens.
Studying proteolysis is tough, as the oft-used polypeptide reporters are vulnerable to proteolytic sequestration themselves. Here we current a brand new method that permits the imaging of antigen proteolysis all through the processing pathway in an unbiased method. By incorporating bioorthogonal functionalities into the protein in place of methionines, antigens will be adopted throughout degradation, while leaving reactive sidechains open to templated and non-templated post-translational modifications, corresponding to citrullination and carbamylation.
Using this method, we adopted and imaged the post-uptake destiny of the generally used antigen ovalbumin, in addition to the post-translationally citrullinated and/or carbamylated auto-antigen vinculin in rheumatoid arthritis, revealing variations in antigen processing and presentation. Zika virus (ZIKV) has emerged as an vital world well being risk, with the not too long ago acquired capability to trigger extreme neurological signs and to persist inside host tissues.
We beforehand demonstrated that an early Asian lineage ZIKV isolate induces a extremely activated CD8 T cell response particular for an immunodominant epitope in the ZIKV envelope protein in wild-type mice. Here we present {that a} modern ZIKV isolate from the Brazilian outbreak severely limits CD8 T cell immunity in mice and blocks era of the immunodominant CD8 T cell response. This is related to a extra sustained an infection that’s cleared between 7- and 14-days post-infection.
Mechanistically, we show that an infection with the Brazilian ZIKV isolate reduces the cross-presentation capability of dendritic cells and fails to completely activate the immunoproteasome. Thus, our examine supplies an isolate-specific mechanism of host immune evasion by one Brazilian ZIKV isolate, which differs from the early Asian lineage isolate and supplies potential perception into viral persistence related to current ZIKV outbreaks.
Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy considerably will increase the efficiency of anti-PD1 checkpoint remedy
Clinical immunotherapy approaches are missing efficacy in the therapy of glioblastoma (GBM). In this examine, we sought to reverse native and systemic GBM-induced immunosuppression utilizing the Helicobacter pylori neutrophil-activating protein (NAP), a potent TLR2 agonist, as an immunostimulatory transgene expressed in an oncolytic measles virus (MV) platform, retargeted to permit viral entry by means of the urokinase-type plasminogen activator receptor (uPAR).
While single-agent murine anti-PD1 therapy or repeat in situ immunization with MV-s-NAP-uPA offered modest survival profit in MV-resistant syngeneic GBM fashions, the mixture therapy led to synergy with a remedy charge of 80% in mice bearing intracranial GL261 tumors and 72% in mice with CT-2A tumors.
Combination NAP-immunovirotherapy induced huge inflow of lymphoid cells in mouse mind, with CD8+ T cell predominance; therapeutic efficacy was CD8+ T cell dependent. Inhibition of the IFN response pathway utilizing the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the mind and additional potentiated the therapeutic impact of MV-s-NAP-uPA and anti-PD1.
Our findings help the notion that MV strains armed with bacterial immunostimulatory antigens signify an efficient technique to beat the restricted efficacy of immune checkpoint inhibitor-based therapies in GBM, making a promising translational technique for this deadly mind tumor. One case was optimistic for HLA class I and HLA class II antibodies, whereas 9 circumstances have been optimistic for HLA class II antibodies, and the gene loci have been HLA-DR and/or DQ.
Antibody-mediated rejection (AMR) occurred in 4 of 10 sufferers in the DSA-positive group. Liver perform was irregular in 3 of 38 circumstances in the DSA-negative group. Multivariate evaluation revealed that DSA positivity was an impartial danger issue for liver insufficiency and long-term survival of recipients. In addition, Kaplan-Meier survival evaluation demonstrated that there have been vital variations in the survival of graft recipients between the DSA-positive group and the DSA-negative group (P<0.05).
E. coli Antibody |
|||
| abx021671-02ml | Abbexa | 0.2 ml | 594 EUR |
E. coli Antibody |
|||
| abx021672-1mg | Abbexa | 1 mg | 1045.2 EUR |
E. coli Antibody |
|||
| abx021673-1mg | Abbexa | 1 mg | 1045.2 EUR |
E. coli Antibody |
|||
| abx022970-1ml | Abbexa | 1 ml | 878.4 EUR |
E. coli Antibody |
|||
| abx022971-1ml | Abbexa | 1 ml | 1161.6 EUR |
E. coli Antibody |
|||
| abx022975-1ml | Abbexa | 1 ml | 718.8 EUR |
E. coli Antibody |
|||
| abx022977-1ml | Abbexa | 1 ml | 811.2 EUR |
Escherichia coli (E. coli) Antibody |
|||
| abx415692-01mg | Abbexa | 0.1 mg | 760.8 EUR |
Escherichia coli (E. coli) Antibody |
|||
| abx415712-1ml | Abbexa | 1 ml | 727.2 EUR |
Escherichia coli (E. coli) Antibody |
|||
| abx411320-1ml | Abbexa | 1 ml | 610.8 EUR |
Escherichia coli (E. coli) Antibody (Biotin) |
|||
| abx415713-1ml | Abbexa | 1 ml | 861.6 EUR |
Escherichia coli (E. coli) Antibody (Biotin) |
|||
| abx411321-1ml | Abbexa | 1 ml | 710.4 EUR |
Escherichia coli (E. coli) Antibody (FITC) |
|||
| abx411322-1ml | Abbexa | 1 ml | 610.8 EUR |
E. coli antibody (FITC) |
|||
| 60-E13 | Fitzgerald | 1 ml | 453.6 EUR |
|
Description: Rabbit polyclonal E. coli antibody (FITC) conjugated |
|||
E. coli antibody (biotin) |
|||
| 60-E13B | Fitzgerald | 1 ml | 561.6 EUR |
|
Description: Rabbit polyclonal E. coli antibody (biotin) conjugated |
|||
E. coli antibody (HRP) |
|||
| 60-E14 | Fitzgerald | 1 ml | 489.6 EUR |
|
Description: Rabbit polyclonal E. coli antibody (HRP) conjugated |
|||
E. coli O157 antibody |
|||
| 10-1490 | Fitzgerald | 100 ug | 163.2 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody |
|||
E. coli O157 antibody |
|||
| 10-1521 | Fitzgerald | 100 ug | 170.4 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody |
|||
E. coli O157 antibody |
|||
| 10-E12A | Fitzgerald | 100 ug | 462 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody |
|||
E. coli DnaJ Antibody |
|||
| 32022-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli pykF Antibody |
|||
| 32163-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli GOR Antibody |
|||
| 32540-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli CysH Antibody |
|||
| 30281-05111 | AssayPro | 150 ug | 313.2 EUR |
E. Coli HCP antibody |
|||
| 20R-EG001 | Fitzgerald | 1 ml | 1004.4 EUR |
|
Description: Goat polyclonal E. Coli HCP antibody |
|||
E. coli NDK Antibody |
|||
| 32662-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli PPA Antibody |
|||
| 32678-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli glk Antibody |
|||
| 32864-05111 | AssayPro | 150 ug | 313.2 EUR |
E. Coli ldhA Antibody |
|||
| 32898-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli deoC Antibody |
|||
| 32936-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli Skp Antibody |
|||
| 32971-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli nanA Antibody |
|||
| 33092-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli O157 antibody |
|||
| 10C-CR1295M3 | Fitzgerald | 100 ug | 470.4 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody |
|||
E. coli GroEL Antibody |
|||
| 20012-05011 | AssayPro | 150 ug | 260.4 EUR |
E. coli O157 Antibody |
|||
| abx021684-1mg | Abbexa | 1 mg | 1220.4 EUR |
E. coli O157 Antibody |
|||
| abx021685-1mg | Abbexa | 1 mg | 1195.2 EUR |
E. coli O157 Antibody |
|||
| abx021686-1mg | Abbexa | 1 mg | 1195.2 EUR |
E. coli O157 Antibody |
|||
| abx021687-1mg | Abbexa | 1 mg | 1195.2 EUR |
E. coli O157 Antibody |
|||
| abx021688-1mg | Abbexa | 1 mg | 1128 EUR |
E. coli O157 Antibody |
|||
| abx021689-1mg | Abbexa | 1 mg | 1195.2 EUR |
E. coli Antibody (HRP) |
|||
| abx022972-1ml | Abbexa | 1 ml | 718.8 EUR |
E. coli Antibody (FITC) |
|||
| abx022974-1ml | Abbexa | 1 ml | 777.6 EUR |
E. coli Antibody (Biotin) |
|||
| abx022976-1ml | Abbexa | 1 ml | 718.8 EUR |
E. coli Antibody (HRP) |
|||
| abx022978-1ml | Abbexa | 1 ml | 1053.6 EUR |
E. coli Antibody (Biotin) |
|||
| abx022979-1ml | Abbexa | 1 ml | 886.8 EUR |
E. coli O157 Antibody |
|||
| abx024017-1mg | Abbexa | 1 mg | 1212 EUR |
E. coli O157 Antibody |
|||
| V3307-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli. |
|||
E. coli O157 Antibody |
|||
| V3307-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli. |
|||
E. coli O157 Antibody |
|||
| V3307SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli. |
|||
E. coli GroL |
|||
| DAG1704 | Creative Diagnostics | 100 ug | 1098 EUR |
E. coli GroS |
|||
| DAG1705 | Creative Diagnostics | 100 ug | 1098 EUR |
E. coli DsbA |
|||
| DAG1712 | Creative Diagnostics | 100 ug | 1098 EUR |
E. coli GrpE |
|||
| DAG1714 | Creative Diagnostics | 100 ug | 1232.4 EUR |
Leukemia - ALL Exosome |
|||
| P141-ALL | 101Bio | - | Ask for price |
Leukemia - ALL Exosome RNA |
|||
| P241-ALL | 101Bio | - | Ask for price |
E. coli O157 antibody (FITC) |
|||
| 61C-CR1295M1F | Fitzgerald | 100 ug | 489.6 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody (FITC) |
|||
E. coli O157 antibody (FITC) |
|||
| 61C-CR1295M4F | Fitzgerald | 100 ug | 561.6 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody (FITC) |
|||
E. coli O157:H7 antibody |
|||
| 70-XG13 | Fitzgerald | 1 mg | 734.4 EUR |
|
Description: Affinity purified Goat polyclonal E. coli O157:H7 antibody. |
|||
E. coli antibody (K99 Pilus) |
|||
| 10-E20A | Fitzgerald | 500 ug | 591.6 EUR |
|
Description: Mouse monoclonal E. coli antibody (K99 Pilus) |
|||
E. coli Tryptophanase (Tnase) Antibody |
|||
| 33517-05111 | AssayPro | 150 ug | 313.2 EUR |
E. coli Glycerol Kinase Antibody |
|||
| 32699-05111 | AssayPro | 150 ug | 313.2 EUR |
Mouse antibody for E. coli |
|||
| 1063 | Virostat | 100 ug | 438.46 EUR |
|
Description: This is Mouse monoclonal FITC conjugated antibody against E coli O157 for WB, ELISA. |
|||
E. coli Enterotoxin B Antibody |
|||
| abx021678-1mg | Abbexa | 1 mg | 718.8 EUR |
E. coli Enterotoxin B Antibody |
|||
| abx021679-1mg | Abbexa | 1 mg | 727.2 EUR |
E. coli Enterotoxin B Antibody |
|||
| abx021680-1mg | Abbexa | 1 mg | 718.8 EUR |
E. coli O157 Antibody (FITC) |
|||
| abx021683-1mg | Abbexa | 1 mg | 2798.4 EUR |
E. coli O157:H7 Antibody |
|||
| abx022980-1mg | Abbexa | 1 mg | 718.8 EUR |
E. coli Enterotoxin LT Antibody |
|||
| abx023834-1mg | Abbexa | 1 mg | 878.4 EUR |
E. coli Enterotoxin LT Antibody |
|||
| abx023835-1mg | Abbexa | 1 mg | 878.4 EUR |
E. coli Enterotoxin LT Antibody |
|||
| abx023836-1mg | Abbexa | 1 mg | 878.4 EUR |
E. coli Enterotoxin LT Antibody |
|||
| abx023837-1mg | Abbexa | 1 mg | 878.4 EUR |
E. coli Enterotoxin STp Antibody |
|||
| abx023838-1mg | Abbexa | 1 mg | 1053.6 EUR |
E. coli Enterotoxin STp Antibody |
|||
| abx023839-1mg | Abbexa | 1 mg | 1053.6 EUR |
E. coli Enterotoxin STp Antibody |
|||
| abx023840-1mg | Abbexa | 1 mg | 1053.6 EUR |
E. coli O157 (9.88) Antibody |
|||
| BNC040207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF405S conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC040207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF405S conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC050207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF405M conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC050207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF405M conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCAP0207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCAP0207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCB0207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Biotin conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCB0207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Biotin conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCP0207-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),PerCP conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCR0207-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),RPE conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC940207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF594 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC940207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF594 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCA0207-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),APC conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC810207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF680R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC810207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF680R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNUB0207-100 | Biotium | 100uL | 250.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88), Concentration: 0.2mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNUB0207-500 | Biotium | 500uL | 549.6 EUR |
|
Description: Primary antibody against E. coli O157 (9.88), Concentration: 0.2mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCH0207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCH0207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC880207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF488A conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC880207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF488A conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC680207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF568 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC680207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF568 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC470207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF647 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC470207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF647 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC430207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF543 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC430207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF543 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC610207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF660R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC610207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF660R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC800207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF680 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC800207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF680 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC400207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF640R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC400207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF640R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC550207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF555 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC550207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF555 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC700207-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF770 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC700207-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF770 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNUM0207-50 | Biotium | 50uL | 474 EUR |
|
Description: Primary antibody against E. coli O157 (9.88), 1mg/mL |
|||
Rabbit Anti-E. coli all ag's Polyclonal Antibody |
|||
| DPAB0123 | Creative Diagnostics | 1 ml | 999.6 EUR |
Rabbit Anti-E. coli all ag's Polyclonal Antibody |
|||
| DPAB0126 | Creative Diagnostics | 1 ml | 1146 EUR |
Escherichia coli Serotype O2 (E. coli O2) Antibody |
|||
| abx411330-02mg | Abbexa | 0.2 mg | 678 EUR |
Escherichia coli Serotype O15 (E. coli O15) Antibody |
|||
| abx411331-02mg | Abbexa | 0.2 mg | 678 EUR |
Escherichia coli Serotype O20 (E. coli O20) Antibody |
|||
| abx411332-02mg | Abbexa | 0.2 mg | 678 EUR |
Chlamydia trachomatis (EB's all antigens) Antibody |
|||
| abx022942-1ml | Abbexa | 1 ml | 710.4 EUR |
E. Coli Recombinant TRXB |
|||
| 6331-100 | Biovision | 510 EUR | |
E. Coli Recombinant SlyD |
|||
| 6366-100 | Biovision | 548.4 EUR | |
E. coli RecA Protein |
|||
| 01-001 | Sceti | 200 ug | 246 EUR |
|
Description: The E. coli RecA Protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli LexA repressor |
|||
| 01-005 | Sceti | 50 ug | 574.8 EUR |
|
Description: The E. coli LexA repressor is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli LexA repressor |
|||
| 01-006 | Sceti | 250 ug | 1420.8 EUR |
|
Description: The E. coli LexA repressor is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvA protein |
|||
| 01-007 | Sceti | 50 ug | 574.8 EUR |
|
Description: The E. coli RuvA protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvA protein |
|||
| 01-008 | Sceti | 250 ug | 1420.8 EUR |
|
Description: The E. coli RuvA protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvB protein |
|||
| 01-009 | Sceti | 50 ug | 574.8 EUR |
|
Description: The E. coli RuvB protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvB protein |
|||
| 01-010 | Sceti | 250 ug | 1420.8 EUR |
|
Description: The E. coli RuvB protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvC protein |
|||
| 01-011 | Sceti | 50 ug | 574.8 EUR |
|
Description: The E. coli RuvC protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvC protein |
|||
| 01-012 | Sceti | 250 ug | 1420.8 EUR |
|
Description: The E. coli RuvC protein is available in Europe and for worldwide shipping via Gentaur. |
|||
TesA, E. coli esterase |
|||
| 0306-1 | AthenaES | 100 Units | 505.2 EUR |
TesA, E. coli esterase |
|||
| 0306-5 | AthenaES | 500 Units | 2046 EUR |
E. coli O 157 |
|||
| abx291002-100mg | Abbexa | 100 mg | 744 EUR |
Benzonase, E. Coli Recombinant |
|||
| 7680-25 | Biovision | 398.4 EUR | |
Benzonase, E. Coli Recombinant |
|||
| 7680-5 | Biovision | 164.4 EUR | |
E. coli FimC [His] |
|||
| DAG1666 | Creative Diagnostics | 100 ug | 1232.4 EUR |
E. coli Eco [His] |
|||
| DAG1667 | Creative Diagnostics | 50 ug | 1232.4 EUR |
E. coli DNA Ligase |
|||
| M1217-100 | Biovision | 385.2 EUR | |
E. coli Exonuclease I |
|||
| M1222-100 | Biovision | 301.2 EUR | |
E. coli Exonuclease III |
|||
| M1223-100 | Biovision | 320.4 EUR | |
RecA Protein E. coli |
|||
| M1231-200 | Biovision | 242.4 EUR | |
E. coli Recombinant IDNK |
|||
| P1050-10 | Biovision | 196.8 EUR | |
E. coli Recombinant IDNK |
|||
| P1050-50 | Biovision | 457.2 EUR | |
Recombinant E. coli, Glucokinase |
|||
| P1054-10 | Biovision | 196.8 EUR | |
Recombinant E. coli, Glucokinase |
|||
| P1054-50 | Biovision | 457.2 EUR | |
Enterotoxin STp (E. coli) |
|||
| H-6248.0500 | Bachem | 0.5mg | 835.2 EUR |
|
Description: Sum Formula: C81H110N20O26S6; CAS# [115474-04-9] net |
|||
Enterotoxin STp (E. coli) |
|||
| H-6248.1000 | Bachem | 1.0mg | 1416 EUR |
|
Description: Sum Formula: C81H110N20O26S6; CAS# [115474-04-9] net |
|||
E. coli Topoisomerase IV |
|||
| TG2000EC-1 | TopoGen | 250 units | 537.6 EUR |
E. coli Topoisomerase IV |
|||
| TG2000EC-3 | TopoGen | 500 units | 819.6 EUR |
E. coli Topoisomerase IV |
|||
| TG2000EC-5 | TopoGen | 1000 units | 1262.4 EUR |
E. coli DNA Gyrase |
|||
| TG2000G-1 | TopoGen | 100 units | 388.8 EUR |
E. coli DNA Gyrase |
|||
| TG2000G-3 | TopoGen | 500 units | 846 EUR |
The positivity of DSAs after pediatric liver transplantation was intently associated to the incidence of AMR. These outcomes prompt that DSAs needs to be routinely monitored post-operatively, and that DSA-positive recipients needs to be screened as quickly as attainable and given acceptable therapy.